Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21406020 | 0.88 | PANK3 (0.57) | TP53MAPTLMNASMN1; SMN2KDM4E | |
| SCHEMBL26501555 | 0.85 | KMT2A (0.59) | TP53MAPTLMNASMN1; SMN2KDM4E | |
| SCHEMBL23750583 | 0.81 | MKNK1 (0.52) | DEGS1MEN1KMT2A | |
| SCHEMBL24103799 | 0.81 | DEGS1 (0.58) | TP53MAPTALDH1A1DEGS1L3MBTL1 | |
| SCHEMBL21424095 | 0.75 | DEGS1 (0.49) | DEGS1MEN1KMT2A | |
| SCHEMBL21406433 | 0.74 | PANK3 (0.71) | TP53MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL26702781 | 0.74 | LMNA (0.51) | TP53MAPTLMNASMN1; SMN2KDM4E | |
| SCHEMBL16769751 | 0.74 | ACACB (0.49) | TP53MAPTLMNASMN1; SMN2KDM4E | |
| SCHEMBL20841045 | 0.72 | LMNA (0.48) | TP53MAPTLMNASMN1; SMN2KDM4E | |
| SCHEMBL26502436 | 0.72 | PANK3 (0.44) | LMNAALDH1A1PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | TP53 3054/4885MAPT 1819/4885LMNA 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.